OBJECTIVES: Although anti-tumor necrosis factor (TNF) therapy is the treatment of choice
for perianal fistulizing Crohn's disease (CD), the efficacy and safety of anti-TNF therapy in …

Background: Internal fistula in Crohn's disease is a condition likely to require surgery,
although few reports showed successful medical treatments such as anti–tumor necrosis …

Background Fistulas occur in about 25% of patients with Crohn's disease (CD) and can be
difficult to treat. The aim of this consensus was to provide guidance for the management of …

Tumor necrosis factor (TNF) antagonists are considered the cornerstone therapy for
fistulizing perianal Crohn's disease (PCD), yet a substantial proportion of patients fail to …

Objective. Intravenously administered infliximab, a monoclonal antibody directed against
tumor necrosis factor-α, has been proven to be efficacious in the treatment of fistulas in …

Background & Aims Few data are available on the effects of tumor necrosis factor (TNF)
antagonist therapy for patients with internal fistulizing Crohn's disease (CD) and there is …

Background & Aims Little is known about the long-term efficacy of infliximab for patients with
fistulizing perianal Crohn's disease. We evaluated outcomes and predictors of outcomes in …

Objective Limited data are available regarding the relationship between anti-tumor necrosis
factor (TNF) drug/antibody levels and perianal fistula outcomes in Crohn's disease. The aims …

Perianal fistulas occur in approximately 30% of patients with Crohn's disease (CD).
Infliximab, a chimeric monoclonal antibody targeting human tumor necrosis factor alpha …

Objectives: Anti-TNF agents are effective to treat perianal Crohn's disease (CD). Evidence
suggests that Crohn's disease patients with perianal fistulas need higher infliximab (IFX) …